NEW YORK (GenomeWeb News) – Agilent Technologies today reported a 9 percent drop in fourth-quarter revenues for its Bioanalytical segment, including a 7 percent dip in life science receipts.

The slowing sales in Agilent's Bioanalytical segment contributed to an overall 21 percent drop in company-wide Q4 revenues and an 89 percent decline in net income.

For the fourth quarter ended Oct. 31, 2009, Agilent's Bioanalytical group reported revenues of $544 million compared to $594 million for Q4 2008.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Sponsored by

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Sponsored by

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.